(go to content)

Castellano | Euskara | Français | English

 Imagen decorativa
DTB: Vol 24, No 5

Content tools

Share it

  • Meneame
  • Delicious
  • Twitter
  • Google
  • Facebook

Contribution of bronchodilator combination therapies to COPD

No clinically relevant differences were observed between LAMA+LABA combination therapies and LAMA monotherapy. The effectiveness of LAMA+LABA combinations in preventing exacerbations was only assessed with indacaterol / glycopyrronium, with modest results. The validity of comparative studies of LAMA+LABA vs. LABA+ corticosteroids was compromised by pre-trial exclusions of specific patients, and the inclusion of patients for whom a LABA+corticosteroid was contraindicated. A lack of scientific evidence exists to support the use of LAMA+LABA as first-choice therapy for COPD.

      Download pdf


  • Javier Garjón. Head of de Primary Care Unit. Subdirectorate of Pharmacy. Navarre Health Service, Spain
Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)






Government of Navarre

Contact us | Accessibility | Legal notice | Site map